Please login to the form below
Medicis rated 'Strong Sell' on weak dermatology sales
Analysts give US-based Medicis Pharmaceutical a "Strong Sell" rating after dermatology sales disappoint
Matrix Research analysts have given US-based Medicis Pharmaceutical a "Strong Sell" rating.
Analysts say that the company's dermatology sales had risen only four per cent over the eight-quarter period ended June 2007. With a 40 per cent rise in Medicis' capital over the period, the company's return on capital has declined significantly.
In August 2007, Swedish biotechnology company Q-Med said it was eyeing a merger with Medicis.
Q-Med's CEO, Bengt Agerup, who owns 47.5 per cent of the firm, said that a union with Medicis made "industrial sense". The company had partnered with Medicis on the marketing of the Swedish firm's cosmetic filler Restylane.
No concrete merger talks were ongoing at the time, but if the valuations of the company changed, talks might be initiated, added Agerup.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
